Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  1997-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/01.ATV.17.11.3215PMID 9409314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis.

  1996cited by this paper
• Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL.

  1996cited by this paper
• Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells.

  1995cited by this paper
• Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.

  1995cited by this paper
• Determinants of Plasminogen Activator Inhibitor 1 Activity in Treated NIDDM and Its Relation to a Polymorphism in the Plasminogen Activator Inhibitor 1 Gene

  1995cited by this paper
• Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture.

  1995cited by this paper
• The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study

  1995cited by this paper
• Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.

  1995cited by this paper
• Differentiation of human osteoblastic cells in culture

  1995cited by this paper
• Plasminogen Activator Inhibitor Type-1 Determines Plasmin Formation in Patients with Ischaemic Heart Disease

  1995cited by this paper
• Plasminogen Activator Inhibitor-1 (PAI-1) Promoter Polymorphism and Coronary Artery Disease in Non-Insulin-Dependent Diabetes

  1995cited by this paper
• The insulin resistance syndrome in smokers is related to smoking habits.

  1994cited by this paper
• Regulation of plasminogen activation by interleukin-6 in human lung fibroblasts.

  1994cited by this paper
• Subunit composition of lipoprotein(a) protein.

  1994cited by this paper
• Polymorphisms of the Plasminogen Activator Inhibitor- 1 Gene in Type 1 and Type 2 Diabetes, and in Patients with Diabetic Retinopathy

  1994cited by this paper
• Polymorphic forms of Lp(a) with different structural and functional properties: cold-induced self-association and binding to fibrin and lysine-Sepharose.

  1994cited by this paper
• The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.

  1993cited by this paper
• Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

  1993cited by this paper
• Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells

  1992cited by this paper
• Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina.

  1992cited by this paper
• Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.

  1992cited by this paper
• Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression.

  1992cited by this paper
• Urokinase binding and receptor identification in cultured endothelial cells.

  1991cited by this paper
• Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.

  1991cited by this paper
• Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.

  1991cited by this paper
• Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta.

  1991cited by this paper
• Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up

  1991cited by this paper
• Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells.

  1991cited by this paper
• Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.

  1990cited by this paper
• The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease

  1990cited by this paper
• Isolation and interrelationships of the multiple molecular tissue-type and urokinase-type plasminogen activator forms produced by cultured human umbilical vein endothelial cells.

  1988cited by this paper
• Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus

  1988cited by this paper
• Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter.

  1988cited by this paper
• Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.

  1987cited by this paper
• Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

  1987cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• Plasminogen activator inhibitors.

  1987cited by this paper
• Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.

  1986cited by this paper
• Plasminogen activator inhibitor in the blood of patients with coronary artery disease.

  1985cited by this paper
• Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene.

  1985cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper
• Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene

  1984cited by this paper
• Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein

  1984cited by this paper
• Isolation and characterization of a urokinase-type plasminogen activator (Mr = 54,000) from cultured human endothelial cells indistinguishable from urinary urokinase.

  1984cited by this paper
• A Direct, Plasmin Independent Assay For Plasminogen Activation

  1984cited by this paper
• Human endothelial cells: use of heparin in cloning and long-term serial cultivation.

  1983cited by this paper
• Characterization and properties of cultured human von Willebrand umbilical vein endothelial cells.

  1981cited by this paper
• An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization.

  1979cited by this paper
• Cultured aortic endothelial cells from pigs with von Willebrand disease: in vitro model for studying the molecular defect(s) of the disease.

  1977cited by this paper
• Culture of Arterial Endothelial Cells

  1975cited by this paper
• Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

  1973cited by this paper

• Dietary Fats and the Gut Microbiota: Their impacts on lipid-induced metabolic syndrome

  2022cites this paper
• Severe Hepatic Insulin Resistance Induces Vascular Dysfunction: Improvement by Liver-Specific Insulin Receptor Isoform A Gene Therapy in a Murine Diabetic Model

  2021cites this paper
• Bioactive lipids in metabolic syndromes and hemostatic factors and fibrinolysis

  2021cites this paper
• A SHORT STUDY ON THE CLINICO PATHOLOGICAL CORRELATION OF SERUM HOMOCYSTEINE LEVEL

  2020cites this paper
• Cyanidin-3-O-glucoside ameliorates palmitate-induced insulin resistance by modulating IRS-1 phosphorylation and release of endothelial derived vasoactive factors.

  2017cites this paper
• An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.

  2016influential citation
• Lipoprotein(a) and livedoid vasculopathy: A new thrombophilic factor?

  2015cites this paper
• Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke

  2013cites this paper
• 2 Lipoprotein ( a ) Oxidation , Autoimmune and Atherosclerosis

  2012cites this paper
• Lipoprotein(a) Oxidation, Autoimmune and Atherosclerosis

  2012cites this paper
• Type 2 Diabetes and Fibrinolysis

  2011cites this paper
• Evaluation of the possible contribution of antioxidants administration in metabolic syndrome.

  2011cites this paper
• Role of homocysteine and lipoprotein (A) in atherosclerosis: An update

  2011cites this paper
• Association between diet quality and metabolic syndrome in overweight and obese postmenopausal women

  2011cites this paper
• Impaired Fibrinolysis in the Antiphospholipid Syndrome

  2010cites this paper
• Lipoprotein (a) and Stroke: An Overview

  2010cites this paper
• Régulation de protéine C-réactive vasculaire dans le diabète de type 2

  2010cites this paper
• Lipoprotein a: where are we now?

  2009cites this paper
• Novel markers of peripheral arterial disease

  2009cites this paper
• PAI‐1 activity, but not fibrinogen or von Willebrand factor, is inversely related to LDL particle size in type 2 diabetes

  2008cites this paper
• Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: Lessons from the liver

  2008cites this paper
• Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

  2007cites this paper
• Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI‐1 gene

  2006cites this paper
• The MAPK Pathway and HIF‐1 Are Involved in the Induction of the Human PAI‐1 Gene Expression by Insulin in the Human Hepatoma Cell Line HepG2

  2006cites this paper
• Visceral Fat as a Determinant of Fibrinolysis and Hemostasis

  2005cites this paper
• Effects of oestrogen receptor‐active compounds on lipid metabolism

  2005cites this paper
• Identification of a novel gene, HCR2, in aorta of hypercoagulable rats using suppression subtractive hybridization.

  2005cites this paper
• Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk

  2004cites this paper
• Effects of lipids and lipid‐lowering therapy on hemostatic factors in patients with myocardial infarction

  2004cites this paper
• Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.

  2004cites this paper
• Insulin Resistance and Cardiovascular Disease: New Insights from Genetics

  2004cites this paper
• Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis.

  2003cites this paper
• Hereditary and acquired defects in the fibrinolytic system associated with thrombosis.

  2003cites this paper
• Emerging Risk Factors for Atherosclerotic Vascular Disease

  2003cites this paper
• Lipoproteína(a) y aterotrombosis

  2003cites this paper
• Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence.

  2003cites this paper
• Induction of atherosclerosis by human chylomicron remnants: a hypothesis.

  2003cites this paper
• Obesity, haemostasis and the fibrinolytic system

  2002cites this paper
• Insulin resistance syndrome : clustering of thrombotic risk factors Insulin Resistance Syndrome

  2002cites this paper
• The Independence of Signaling Pathways Mediating Increased Expression of Plasminogen Activator Inhibitor Type 1 in HepG2 Cells Exposed to Free Fatty Acids or Triglycerides

  2002cites this paper
• Insulin resistance syndrome: interaction with coagulation and fibrinolysis.

  2002cites this paper
• [Characteristics of mixed hyperlipidemia cases in a population-based study: results from the Mexican National Survey of Chronic Diseases].

  2002cites this paper
• Características de los casos con dislipidemias mixtas en un estudio de población: resultados de la Encuesta Nacional de Enfermedades Crónicas

  2002cites this paper
• Endotelio en la protección vascular: nuevos conocimientos

  2002cites this paper
• A Critical Evaluation of the Role of Lp(a) in Cardiovascular Disease: Can Lp(a) Be Useful in Risk Assessment?

  2002cites this paper
• Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis.

  2001cites this paper
• Comparison of the effects of O2*-/HO* free radical- and copper ions-oxidized LDL or lipoprotein(a) on the endothelial cell releases of tissue plasminogen activator and plasminogen activator inhibitor-1.

  2001cites this paper
• Abnormalities in apo B‐containing lipoproteins in diabetes and atherosclerosis

  2001cites this paper
• Insulin resistance and cardiovascular disease.

  2000cites this paper
• PERSPECTIVE SERIES On diabetes : insulin resistance

  2000cites this paper
• Ethanol downregulates transcription of the PAI-1 gene in cultured human endothelial cells.

  2000cites this paper
• Lipoprotein(a): from ancestral benefit to modern pathogen?

  2000cites this paper
• Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells.

  2000cites this paper
• Ethanol-induced up-regulation of candidate plasminogen receptor annexin II in cultured human endothelial cells.

  2000cites this paper
• Lipoprotein Lp(a) and atherothrombotic disease.

  2000cites this paper
• Hereditary Defects in Fibrinolysis Associated with Thrombosis

  1999cites this paper
• Endothelial cell fibrinolysis: transcriptional regulation of fibrinolytic protein gene expression (t-PA, u-PA, and PAI-1) by low alcohol.

  1999cites this paper
• Lipoprotein(a) and coronary heart disease risk

  1999cites this paper
• Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.

  1999cites this paper
• Antipeptide antibodies reveal interrelationships of MBP 200 and MBP 235: unique apoB-specific receptors for triglyceride-rich lipoproteins on human monocyte-macrophages.

  1999cites this paper
• Triglycerides as a risk factor in cardiac heart disease

  1999cites this paper
• Pathophysiology of triglyceride‐rich lipoproteins in atherothrombosis: Cellular aspects

  1999cites this paper
• Lipids and the endothelium.

  1999cites this paper
• Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells.

  1999cites this paper
• Lipoprotein(a), homocysteine, and remnantlike particles: emerging risk factors.

  1999cites this paper
• Expression of Plasminogen Activator Inhibitor Type I in Genotyped Human Endothelial Cell Cultures: Genotype-specific Regulation by Insulin

  1999cites this paper
• Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells.

  1998cites this paper
• Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease.

  1998cites this paper
• Ethanol transcriptionally upregulates t-PA and u-PA gene expression in cultured human endothelial cells.

  1998cites this paper